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Introduction: The majority of patients seeking medical treatment for snakebites do not suffer from
severe envenomation. However, no guidelines exist for ordering coagulation markers in patients with
minimal or moderate envenomation, nor in those who do not receive antivenom. In this study, we
soughtto determinewhetherit was possibleto limit the practice of orderingcoagulationstudies to those
patients suffering severe envenomation, rattlesnake envenomation, or both.
Methods: A retrospective chart review was performed on all cases of crotalid snakebite presenting to
an adult emergency department (ED) from April 1998 to June 2006. Each chart was abstracted for
patient’s age, gender, type of snake (if known), severity of envenomation at initial presentation,
coagulation test results, whether antivenom was administered, and whether the patient was admitted.
Results: Over an approximately 8-year period, 131 snakebite cases presented that met the inclusion
criteria, of which 35 (26.7%) had some type of coagulation marker abnormality. Limiting coagulation
testing to patients suffering severe envenomation or rattlesnake envenomation would have resulted in
failure to identify 89% or 77%, respectively, of the 35 patients who were found to have at least 1
abnormal coagulation marker.
Conclusion: Our study failed to identify a subset of patients that could be defined as low risk or for
whom coagulation marker testing could be foregone. This study suggests that coagulation tests should
be routinely performed on all patients presenting to the ED with complaints of envenomation by
copperheads, moccasins, or rattlesnakes. Further clarification of when coagulation markers are
indicated may require a prospective study that standardizes snake identification and the timing of
coagulation marker testing. [West J Emerg Med. 2012;13(1):68–74.]
INTRODUCTION
More than 2,800 venomous snakebiteswere reported to the
American Association of Poison Control Centers in 2008.
1
Venomous snakes in the Southeastern United States include
rattlesnakes, copperheads, and water moccasins of the crotalid
family, as well as coral snakes of the elapid family. A small
number of bites by these poisonous snakes are termed dry,
when little or no venom is actually injected and symptoms of
envenomation do not develop. Envenomation is generally
deﬁned as occurrence of a snakebite plus evidence of tissue
damage and can result in a spectrum of clinical symptoms and
laboratory abnormalities from mild, local tissue injury to
systemic illness, including hypotension, neuromuscular
dysfunction, and coagulopathy.
2 For a known envenomation,
standard management includes advanced life support, if
indicated, immobilization of the affected limb, local wound
care, tetanus immunization booster, and analgesia. Patients are
usually observed in the emergency department (ED) setting for
6 to 8 hours. Antivenom (CroFab by Protherics Inc, Brentwood,
Tennessee) is typically given for progressive injury, with
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systemic manifestations, or coagulation abnormalities by
laboratory testing.
2
No clear guidelines exist for ordering coagulation markers
in patients with minimal or moderate envenomation, nor in
those who do not receive antivenom. Many ED physicians
routinely order coagulation markers on all patients with
snakebites, regardless of type of snake or severity of
envenomation. The costs of platelet counts, prothrombin times
(PT), activated partial thromboplastin times (aPTT), and
ﬁbrinogen concentrations are signiﬁcant and contribute to the
expense of the management of these patients. Further costs may
also be incurred simply by keeping the patient in the ED longer
than necessary. In this study, we sought to determine whether
coagulation markers are indicated for all snakebite patients in
our region or whether we could limit the practice to ordering
these tests on only those patients suffering severe
envenomation, rattlesnake envenomation, or both.
METHODS
A retrospective chart review was conducted for all cases of
snakebite presenting to a university medical center adult ED
from April 1998 to June 2006. Prior to chart review, 1
abstractor was trained by the principal investigator on the data
collection process. The abstractor was not blinded to the study’s
hypothesis. Inclusion criteria were age greater than 15 years,
documented historical and clinical evidence of snakebite, and
any of 4 coagulation markers recorded. Exclusion criteria were
a known preexisting coagulopathy or hypercoagulable state,
ED presentation delayed more than 6 hours, charts with
insufﬁcient data to determine the severity of envenomation, and
charts with no coagulation markers recorded. Data was
collected from an electronic medical record system. Data not
included in the electronic record was reviewed in paper charts
to gather remaining data variables. Case information used in
our study included the ED physicians’ notes, nurses’drug
administration notes, and laboratory values.
Each chart was abstracted using a standardized data
collection form for age, gender, type of snake, if known,
severity of envenomation at initial presentation, coagulation
test results (platelet count, PT, aPTT, and ﬁbrinogen
concentration), whether antivenom was administered, and
whether the patient was admitted. In cases where the snake was
not identiﬁed, it was recorded as unknown. Severity of
envenomation at the time of presentation was taken directly
from the physicians’ notes, if documented. If not explicitly
recorded by the ED physician, physical examination and
laboratory data were used to classify the envenomation as
minimal, moderate, or severe using the severity scoring
guidelines published by Gold et al in 2002.
2 The severity
scoring guidelines are detailed in Table 1. When a patient
received antivenom at another hospital prior to transfer to the
ED, thesevials were included in the total number recorded. The
hospital laboratory’s standard ranges were used to determine
whether coagulation markers were normal or abnormal. In
cases where a patient had serial coagulation markers
documented, the most abnormal measurement for each
coagulation marker was used.
Table 1. Guidelines for assessing the severity of North American pit viper envenomations.*
Type of signs
or symptoms
Severity of envenomation
Minimal Moderate Severe
Local Swelling, erythema, or ecchymosis
confined to the site of the bite
Progression of swelling, erythema, or
ecchymosis beyond the site of the
bite
Rapid swelling, erythema, or
ecchymosis involving the entire body
part
Systemic No systemic signs or symptoms Non-life threatening signs and
symptoms (nausea, vomiting,
perioral paresthesias, myokymia,
and mild hypotension)
Markedly severe signs and symptoms
(hypotension [systolic blood
pressure ,80 mm Hg], altered
sensorium, tachycardia, tachypnea,
and respiratory distress)
Coagulation No coagulation abnormalities or other
important laboratory abnormalities
Mildly abnormal coagulation profile
without clinically significant bleeding;
mild abnormalities on other
laboratory tests
Markedly abnormal coagulation profile
with evidence of bleeding or threat
of spontaneous hemorrhage
(unmeasurable INR, APTT, and
fibrinogen; severe thrombocytopenia
with platelet count ,20,000 per
mm
3); results of other laboratory
tests may be severely abnormal
INR, international normalized ratio; APTT, activated partial-thromboplastin time.
* The ultimate grade of severity of any envenomation is determined on the basis of the most severe sign, symptom, or laboratory
abnormality (eg systolic blood pressure ,70 mm Hg in the absence of local swelling should be graded as a severe envenomation).
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Illinois). Chi-square tests were used to test for associations
between nominal variables. Mann-Whitney U and Kruskal-
Wallis H tests were used to test for differences in mean rank of
the dependent variables when there were 2 and more than 2
levels, respectively, of the independent variable. Logistic
regression was also used to test the relationship between
various risk factors and the presence or absence of an abnormal
coagulation marker. The criterion for statistical signiﬁcance
was P , 0.05.
RESULTS
Over the approximately 8-year period, 132 snakebite cases
presenting to the ED met the inclusion criteria. There was only
1 patient bitten by a coral snake, and this patient was excluded
from all subsequent analyses. The study sample of 131
included 87 (66.4%) men and 44 (33.6%) women. The mean
age was 43.3 years (range 16–90). Forty-nine patients (37.4%)
were bitten by copperheads, 29 (22.1%) by moccasins, 17
(13.0%) by rattlesnakes, and 36 patients (27.5%) could not
identify the snake. There were 37 (28.2%) minimal, 86 (65.6%)
moderate, and 8 (6.1%) severe envenomations. Seventy-two
patients (55.0%) received antivenom, 57 (43.5%) did not
receive antivenom, and wewere unable to determine if 2 (1.5%)
patients received antivenom. Among those patients
administered antivenom, a median of 10 vials was used in the
course of their treatment. Thirty-four patients (26.0%) were
admitted to the hospital and the remainder discharged
following ED observation and treatment. During routine
laboratory testing, some type of coagulation marker
abnormality was identiﬁed in 35 (26.7%) of the 131 snakebite
patients. Seventeen (13.8%) had an abnormal PT, 17 (13.9%)
had an abnormal aPTT, 8 (6.2%) had thrombocytopenia, and 5
(13.2%) had abnormal ﬁbrinogen concentrations. The range of
abnormalities is shown in Table 2. In the group of 35 patients
with a coagulation marker abnormality, 89% were classiﬁed as
having amild or moderate envenomation, and 77% did not have
a rattlesnake envenomation. Only 1 of the 131 patients in our
study had documented bleeding in the ED. This patient suffered
a severe rattlesnake envenomation and was noted to have
hematemesis while in the ED.
There were statistically signiﬁcant associations between
the identiﬁed type of snake and PT (P ¼ 0.015), aPTT (P¼
0.043), and ﬁbrinogen (P¼ 0.028) abnormalities. Rattlesnake
envenomation was associated with the greatest rate of
coagulation abnormalities for each marker. Among patients
envenomated by a rattlesnake, approximately 35%,3 5 %, and
40% had abnormal PT, aPTT, and ﬁbrinogen concentrations,
respectively. These percentages were more than double of those
found for other snake types. There was also a signiﬁcant
association between the type of snake identiﬁed and the
systemic symptoms experiencedby the patient (P¼0.035). The
percentage of rattlesnake envenomated patients with systemic
symptomatology (35%) was twice the combined percentages
experienced by patients envenomated by other snake types.
There was no signiﬁcant association found between the snake
type and the frequency of observed thrombocytopenia (Table
3).
There was a signiﬁcant association between the graded
severity of envenomation and a laboratory ﬁnding of a PT
abnormality (P¼0.021) for patients with moderate and severe
envenomations being more likely to have a PT abnormality.
There was also an association between the patient’s systemic
symptomatology and abnormalities found on some of the
coagulation makers (PT [P¼0.063), aPTT [P¼0.066], platelet
[P ¼ 0.005], and ﬁbrinogen [P ¼ 0.001]; Table 4). Sensitivity,
speciﬁcity, and positive and negative values of each risk factor
are shown in Table 5. The association between administration
of antivenom and a ﬁnding of a PTabnormality was signiﬁcant
(P ¼ 0.016), However, the association between administration
of antivenom and a ﬁnding of a ﬁbrinogen abnormality was not
signiﬁcant (P ¼ 0.096; Table 4). Patients with abnormal
ﬁbrinogen concentrations tended to receive more vials of
antivenom as compared to patients with normal concentrations,
though this difference was not found to be statistically
signiﬁcant (P ¼ 0.057; Table 6).
There was a signiﬁcant association between the type of
snake identiﬁed and a decision to administer antivenom (P ¼
0.018). A total of 76% of patients with a rattlesnake
envenomation and 72% of patients with a moccasin
envenomation received antivenom treatment. Only 49% of
patients bitten by a copperhead and 41% of patients
envenomated by an unknown snake type received antivenom
(Table 3). Among patients who received antivenom, therewas a
signiﬁcant difference in the number of vials administrated
during the course of treatment when considering the speciﬁc
snake types identiﬁed (P ¼ 0.002) with rattlesnake victims
receiving twice the number of vials as compared to patients
bitten by other snake types. Patients with abnormal PTT tests
also received more vials of antivenom (P¼0.015) than patients
with other laboratory ﬁndings. We failed to ﬁnd a signiﬁcant
difference in the number of vials administered and observed PT
or platelet abnormalities (Table 6).
We performed an analysis using at least 1 abnormal
coagulation marker as the outcome variable. Rattlesnake bite
(þ/ ) was signiﬁcantly associated with an abnormality (P ¼
0.04), and systemic symptoms were marginally associated with
an abnormality (P¼0.068). Forty-seven percent of rattlesnake
patients had a coagulation marker abnormality versus 23.7% of
nonrattlesnake patients, relative risk was 1.99 (95% conﬁdence
interval [CI], 1.09–3.63). Severity and individual snakes
(copperhead, moccasin, or unknown) failed to reach statistical
signiﬁcance. We then performed a binary logistic regression
using at least 1 coagulation marker as the response variable.
Severity (severe versus not severe), systemic symptoms (þ/ ),
and rattlesnake bite (þ/ ) were used as predictors. The P value
associated with severity was 0.974, and severity was dropped
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symptoms and rattlesnake plus an interaction term as
predictors. The interaction was found to be nonsigniﬁcant (P¼
0.093). Main effects for both systemic symptoms and
rattlesnake bites were signiﬁcant (P¼ 0.044 and P ¼0.035,
respectively). Patients with systemic symptoms had a 13-fold
(odds ratio [OR]) increase in the odds of an abnormal marker
(OR¼ 13.33; 95% CI, 1.069–166.37). A rattlesnake bite was
also associated with 13-fold increase in odds of an abnormal
marker, (95% CI, 1.207–156.64). Finally, we performed a
logistic regression with a dichotomous predictor representing
those positive for both systemic symptoms and rattlesnake bite
and those not positive for both. This dichotomy was a
signiﬁcant predictor (P ¼ 0.013), and being positive for both
systemic symptoms and rattlesnake bite was associated with
increased odds of an abnormal marker of 15.8 (95% CI, 1.779–
140.89). Finally, in this patient population, the positive and
negative predictive values for this dichotomy were 83.3% and
76.0%, respectively (Table 5).
DISCUSSION
While it is common practice to order coagulation studies
on patients with severe snakebite envenomations, the role of
these tests for patients with mild or moderate envenomation is
less certain. In this study, we attempted to determine whether
coagulation markers are critical in the evaluation of all
snakebite patients in our region or whether we could limit the
practice to those patients suffering severe envenomation,
rattlesnake envenomation, or both. The results of this study
indicate that limiting such laboratory studies in this way could
result in a failure to identify a large proportion of patients with
abnormal coagulation markers. Restricting coagulation marker
testing to patients suffering severe envenomation or rattlesnake
envenomation would have resulted in our missing coagulation
marker abnormalities in 89% or 77% patients, respectively.
Restricting coagulation testing to patients with both a
rattlesnake bite and systemic symptoms would have resulted in
missing 86% of patients with coagulation marker
abnormalities.
Table 2. Range of laboratory abnormalities.
Coagulation
markers
Normal
range
Abnormal values
of snakebites
in patients
Abnormal
labs (%)
PLT 130–400 90.0 8/128 (6.30)
96.0
108.0
113.0
114.0
450.0
453.0
548.0
PT 9.3–12.5 s 12.6 17/122 (13.90)
13.6
13.9
14.0
14.0
14.1
14.3
14.5
14.8
15.9
17.1
17.8
21.3
60.0
60.0
100.0
100.0
aPTT 23.9–33.1 s 34.6 17/122 (13.90)
34.7
34.9
35.0
35.5
35.6
35.6
36.2
36.4
37.0
37.7
39.1
39.8
43.0
57.9
100.0
100.0
Table 2. Continued.
Coagulation
markers
Normal
range
Abnormal values
of snakebites
in patients
Abnormal
labs (%)
Fibrinogen 150–400 37.0 5/38 (13.00)
50.0
50.0
135.0
494.0
PLT, platelet; PT, prothrombin time; aPTT, activated partial
thromboplastin times.
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more likely to have abnormal coagulation studies and greater
systemic symptomatology as compared to patients bitten by
other snakes. Also, it was not unexpected that patients with
severe envenomations, and in which a clinical decision to use
antivenom was made, were more likely to have coagulation
marker abnormalities. Most clinicians who routinely treat
snakebites are aware of the importance of performing these
studies in these subsets of snakebite victims. However, in our
experience, this practice has become a routine part of the
evaluation and management of virtuallyall snakebite caseswith
limited objective evidence of necessity or beneﬁt. A
Table 3. Association between snake type and laboratory abnormalities and antivenom use.
Copperhead Moccasin Rattlesnake Unknown n P value
PT abnormality (%) 4.4 18.5 35.3 11.8 123 0.015
aPTT abnormality (%) 13.6 7.4 35.3 8.8 122 0.043
Platelet abnormality (%) 6.3 3.4 6.3 8.3 129 0.833
Fibrinogen abnormality (%) 0.0 10.0 40.0 0.0 38 0.028
Systemic symptoms (%) 6.1 17.2 35.3 19.4 131 0.035
Antivenom use (%) 49.0 72.4 76.5 41.2 129 0.018
PT, prothrombin time; aPTT, activated partial thromboplastin time.
Table 4. Association between coagulation markers and envenomation severity, systemic symptoms, and antivenom use.*
PTþ (%) PTTþ (%) Plateletsþ (%) Fibrinogenþ (%)
Envenomation severity
Minimal 1/35 (2.9) 4/35 (11.4) 2/36 (5.5) 0/6 (0.0)
Moderate 13/80 (16.2) 10/79 (12.6) 5/86 (5.8) 3/26 (11.5)
Severe 3/8 (37.5) 3/8 (37.5) 1/7 (14.3) 2/6 (33.3)
P 0.021 0.136 0.659 0.212
Systemic symptoms
No 12/105 (11.4) 12/104 (11.5) 4/109 (3.7) 1/30 (3.3)
Yes 5/18 (27.7) 5/18 (27.7) 4/20 (20.0) 4/8 (50.0)
P 0.063 0.066 0.005 0.001
Antivenom use
No 3/54 (5.5) 7/54 (12.9) 2/56 (3.5) 0/12 (0.0)
Yes 14/67 (20.9) 9/66 (13.6) 6/71 (8.4) 5/25 (20.0)
P 0.016 0.914 0.261 0.096
PT, prothrombin time; PTT, partial thromboplastin time.
* All denominators represent the row total for the respective coagulation marker, eg of the 35 patients with minimal envenomation severity
and a PT test, 1 had a positive PT test.
Table 5. Sensitivity, specificity, and positive and negative predictive values of risk factors for predicting at least 1 coagulation abnormality.
Values are %, with 95% confidence interval in parentheses.
Risk factor Sensitivity Specificity Predictive value þ Predictive value  
Copperhead 31.4 (17.7–47.7) 60.4 (50.5–69.8) 22.4 (12.4–35.4) 70.7 (60.3–79.8)
Moccasin 17.1 (7.2–31.7) 76.0 (66.9–83.8) 20.7 (8.8–37.5) 71.6 (62.4–79.7)
Rattlesnake 22.9 (11.2–38.4) 90.6 (83.7–95.4) 47.1 (25.0–69.9) 76.3 (68.0–83.5)
Unknown snake type 28.6 (15.5–44.7) 72.9 (63.5–81.1) 27.8 (15.0–43.6) 73.7 (64.3–81.8)
Envenomation severe versus not severe 11.4 (3.7–24.6) 95.8 (90.6–98.7) 50.0 (19.1–80.9) 74.8 (66.7–81.9)
Systemic symptoms yes versus no 25.7 (12.5–43.3) 87.5 (79.2–93.4) 42.9 (21.8–65.9) 76.4 (67.3–83.9)
Systemic symptoms and rattlesnake 14.3 (4.8–30.2) 99.0 (94.3–99.9) 83.3 (35.8–99.5) 76.0 (67.5–83.1)
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testing would not be required could potentially result in better
resource utilization. The most interesting result of this study
was the discovery that coagulation abnormalities were not
conﬁned to patients with severe envenomation, nor to patients
with rattlesnake bites. Coagulation abnormalities were detected
in 24% of patients bitten by copperheads and 15% of patients
bitten by moccasins. Abnormalities were also detected in nearly
one third of patients with moderate envenomation.
Furthermore, 19% of patients whocould not identify the snakes
had some laboratory abnormality. These ﬁndings suggest that
routine coagulation marker testing in nearly all ED patients
with snakebites may be an important part of their clinical
monitoring and management.
LIMITATIONS
There are several reasons that could explain our failure to
identify a subset of patients that do not require coagulation
marker testing. In general, however, the limitations of our study
probably resulted in an underestimation of the prevalence of
coagulation marker abnormalities in the study population.
Difﬁculties involved in accurately identifying a snake type at
the time of a bite event are self evident. Unless documented as
unknown, we assumed that patients correctly identiﬁed the
snakes that bit them. Ninety-ﬁve out of 131 patients in our
study reported being bitten by venomous snakes. This may be
partially accounted for by selection bias; many people bitten by
nonvenomous snakes presumably identify them correctly and
do not seek medical attention. However, the majority of snakes
in our region are nonvenomous, and it is possible that some
patients in our study incorrectly identiﬁed the snakes that bit
them as venomous.
In order to stratify our patients by severity of
envenomation, we used the severity scoring guidelines
published by Gold et al in 2002 (Table 1). These guidelines rely
in part on subjective measurements, such as degree of edema,
erythema, and ecchymosis. In addition, they are designed only
for patients with known envenomation.
2 Nevertheless, we
chose to use this system, as no completely objective tool for
clinical stratiﬁcation currently exists.
Envenomation is also a dynamic process. It is often
difﬁcult to ascertain whether a bite represents true
envenomation on initial ED presentation, and estimations of
dry bites vary widely.
2,3 The amount of venom injected varies
by age, condition, and species of the snake, size of the victim,
and many other factors. The clinical management of snakebites
typically requires a longitudinal monitoring of the patient’s
response to the envenomation, which many also vary greatly
according to the location of the bite and the inherent physiology
of the affected individual. As snake venom is a complex
mixture of enzymes, the clinical responses to envenomation are
myriad.
4 The venom of many snake species contains several
components that can induce hemorrhage, including
ﬁbrinolytics, platelet aggregation inhibitors, and hemorrhagins.
All crotalid snake venoms are theoretically capable of causing
some degree of coagulopathy.
5 Copperhead venom contains a
protein C activator, water moccasins carry beta ﬁbrinogenases,
and timber rattlesnakes carry serine proteases.
4 Case reports
even exist of presumed nonvenomous snakes causing
coagulopathy.
6 This biologic complexity and the evolving
nature of snakebite signs and symptoms may make it difﬁcult to
classify an evenomation as severe early in the course of clinical
management. When considering all these factors, it is perhaps
not surprising to ﬁnd such a prevalence of laboratory
abnormalities among the patients in the current study.
Additionally, not all patients in our study had all 4
coagulation markers (PT, aPTT, platelets, and ﬁbrinogen
concentration) drawn. Timing of patient blood draws also
varied among our patients. In most cases, our patients had their
coagulation markers drawn immediately after being placed in
an ED examination room. However, the delay from the time of
the bite to presentation in the ED varied. Asymptomatic
coagulopathy may, therefore, have occurred in some patients
following their initial blood draw and would not have been
detected in our study. Several case reports and studies exist that
document patients with delayed coagulopathy following
envenomation.
7,8,9
Patient charts were not abstracted for hemoglobin or
hematocrit, so we may have failed to detect occult bleeding
during ED observation. Only 1 patient in 131 had documented
bleeding in the ED. Our study also did not address whether
knowledge of abnormal coagulation markers changed
management or impacted patient outcomes.
CONCLUSION
In this study, we sought to determine whether all patients
presenting to an ED in our region should have coagulation
markers routinely drawn as part of their management. We
hypothesized that this practice could be limited to ordering the
tests only for patients suffering severe envenomation,
Table 6. Median number of antivenom vials administered.
P value
Snake type 0.002
Copperhead 11 (n ¼ 24)
Moccasin 10 (n ¼ 21)
Rattlesnake 17.5 (n ¼ 13)
Unknown 6 (n ¼ 13)
Coagulation marker
PT þ versus – 10 (n ¼ 14) versus 10 (n ¼ 52) 0.726
PTT þ versus – 15 (n ¼ 9) versus 10 (n ¼ 56) 0.015
Platelet þ versus – 11 (n ¼ 6) versus 10 (n ¼ 64) 0.220
Fibrinogen þ versus – 15 (n ¼ 5) versus 10 (n ¼ 19) 0.057
PT, prothrombin time; PTT, partial thromboplastin time.
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identify a group of patients that could be deﬁned as low risk or
for whom coagulation marker testing could be foregone.
Instead, this study suggests that coagulation tests should be
routinely performed on all patients presenting to the ED with
complaints of envenomation by copperheads, moccasins, or
rattlesnakes. The study had a number of limitations, including
snake identiﬁcation, severity of envenomation stratiﬁcation,
and collection of coagulation markers. Further guidance for ED
physicians might be provided by a prospective, multicenter
trial, enrolling only patients for whom the snake could be
positively identiﬁed and in which the same coagulation
markers were drawn at a standardized time.
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